Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California. It manages a multi-strategy platform spanning venture capital, growth equity, buyout, and public equities, focused on biotechnology, pharmaceuticals, medical devices, and healthcare services.
51% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $88.7M (across 150 rounds with reported amounts).
Portfolio
119
Fund Size
$740M
Top Stage
Series B
Last 12 Mo
5
Team
Hao Dong
Managing Director
Albert Chang
Executive Director Head Trader
Nina Feng, M.B.A., C.F.A
Chief Representative of Taiwan Office, Executive Director,Investor Relations
Jiawei Liu
Principal
Brad Sunderland
Associate,Investor Relations
Richard Ding, M.Eng
Analyst
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Terns Pharmaceuticals | Series C | $87M | May 2026 |
 Oricell Therapeutics | Unknown | $110M | Apr 2026 |
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| KKinaset | Series B | $103M | Jan 2026 |
 SonoThera | Series B | $125M | Jan 2026 |
 Sera Prognostics | Series E | $100M | Jan 2026 |
 Serapha Bio | Series A | $138M | Jan 2026 |
 OnKure Therapeutics | Series C | $150M | Jan 2026 |
| IInspira | Series A | $2.8M | Jan 2026 |
 SanegeneBio | Series B | $110M | Jan 2026 |
 BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
 Seran Bioscience | Series C | $200M | Sep 2025 |
| RRonovo | Series D | $67M | Sep 2025 |
 Ronovo Surgical | Series D | $67M | Sep 2025 |
| SSAB Biotherapeutics, Inc. | Series B | $175M | Jul 2025 |
| DDBV Technologies S.A. | Unknown | $306.9M | Mar 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
| SanegeneBio | Series B | $110M | Jan 2025 |
 35 Pharma | Series C | $53M | Nov 2024 |
 Ventyx Biosciences | Series A | $27M | Sep 2024 |
| Seran Bioscience | Growth | $200M | Sep 2024 |
 Zenas BioPharma | Series C | $200M | May 2024 |
 Denali Therapeutics | Series C | $217M | Mar 2024 |
| AAttralus | Series B | $201M | Feb 2024 |
 Neocis | Unknown | $20M | Jan 2024 |
Top Co-Investors
Last updated: 20 October 2026